Log in to your Inderes Free account to see all free content on this page.
Annexin Pharmaceuticals
23.00 SEK
-2.54 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-2.54 %
-13.53 %
-16.67 %
-33.72 %
-45.60 %
-48.90 %
-59.30 %
-73.81 %
-92.81 %
Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
162.36M SEK
Turnover
32.68K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.2.
2026
Annual report '25
All
Press releases
ShowingAll content types
BioStock: Video from Annexin Pharmaceutical's presentation at BioStock Life Science Summit 2025
Redeye: Annexin (Q3’25 Review) - Clinical study in focus
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio